To investigate the potential therapeutic role of the TFEB agonist CC in Alzheimer's disease, firstly, 7-month-old APP/PS1 mice were treated with CC (7, 14 mg/kg) every 3 days to the 12 months of age (Fig. 3A). This evidence concerns the gene APP and early-onset autosomal dominant Alzheimer disease.